TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB‐EGF Expression and Proteolytic Cleavage
Hepatology2019Vol. 72(3), pp. 923–939
Citations Over TimeTop 10% of 2019 papers
Zhao‐Ru Dong, Dong Sun, Yafei Yang, Wei Zhou, Rui Wu, Xiaowei Wang, Kai Shi, Yu‐Chuan Yan, Lun‐Jie Yan, Cheng‐Yu Yao, Zhiqiang Chen, Xu–Ting Zhi, Tao Li
Abstract
HB-EGF can be regulated by TMPRSS4 to promote HCC proliferation, invasion, and angiogenesis, and the combination of the HB-EGF inhibitor cross-reacting material 197 with sorafenib might be used for individualized treatment of HCC.
Related Papers
- → The vasohibin family: a novel family for angiogenesis regulation(2012)113 cited
- → The vasohibin family: Novel regulators of angiogenesis(2012)27 cited
- Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey.(2003)
- A novel in vitro angiogenesis model based on a microfluidic device(2011)
- → A PlGF-1 Derived Peptide Inhibits Angiogenesis via HIF-1β/VEGF Pathway(2016)